Dr. David M. Bear, D.O.

Medicare patients and services

Medicare patients, 2024

1,569

Services billed

107,831

Patients’ average age

72

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 42 companies reported 324 payments worth $139,462 in total to this clinician.

What the payments were for

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Florida →

Industry-funded research

Named as a principal investigator on 12 industry-funded studies in 2025, from 5 companies. The companies reported $1,784,588 in research payments for these studies, mostly to the institutions running them.

• A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)
  Eli Lilly and Company · Active, not recruiting · NCT05026866
• A Pilot Open-Label, Randomized, Multi-Center, Parall el-Arm, of Acute vs Delay Ofatumumab Treatment d uring an Acute Multiple Sclerosis Relapse
  Novartis Pharmaceuticals Corporation
• A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)
  Eli Lilly and Company · Completed · NCT05463731
• An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis
  Novartis Pharmaceuticals Corporation
• A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
  Eli Lilly and Company · Active, not recruiting · NCT04437511
• A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
  Eli Lilly and Company · Active, not recruiting · NCT06653153
• AGNOS: An 18-month, Open-label, Multi-Center Study to Assess the Effect of Ofatumumab 20mg SC Monthly in Treatment Nave, Very Early Relapsing Remitting Multiple Sclerosis Patients Benchmarked Against Healthy Controls …
  Novartis Pharmaceuticals Corporation
• A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
  E.r. Squibb & Sons, L.l.c. · Recruiting · NCT05511363
• Evaluation of the lilly sp-x p-TAU217 assay by measuring changes in the intended patient management between pre-and post-p-TAU217 result: a randomized clinical utility study
  Eli Lilly and Company
• A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease
  Sage Therapeutics, LLC

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Neurology clinicians in Pensacola

• John Axley, M.D.
• Fatima Z. Bensabeur
• Deborah F. Boland, D.O.
• Mark L. Boyer, DO
• Kristin L. Davis, M.D.
• Lien Y. Diep, M.D.
• George M. Dmytrenko, M.D., PH.D.
• Robert A. Frank, M.D.